Valuation: Qiagen N.V.

Capitalization 8.46B 7.2B 6.67B 6.28B 11.69B 786B 11.93B 78.21B 30.6B 378B 31.73B 31.06B 1,346B P/E ratio 2026 *
18.5x
P/E ratio 2027 * 17.5x
Enterprise value 9.04B 7.71B 7.13B 6.71B 12.51B 841B 12.76B 83.65B 32.73B 404B 33.94B 33.22B 1,439B EV / Sales 2026 *
4.08x
EV / Sales 2027 * 3.66x
Free-Float
94.35%
Yield 2026 *
0.33%
Yield 2027 * 0.46%
1 day-0.29%
1 week-0.34%
Current month+2.12%
1 month-0.56%
3 months-13.46%
6 months-17.09%
Current year-13.62%
1 week 39.62
Extreme 39.62
41.78
1 month 38.8
Extreme 38.795
41.78
Current year 38.8
Extreme 38.795
57.82
1 year 38.8
Extreme 38.795
57.82
3 years 38.78
Extreme 38.7765
57.82
5 years 38.78
Extreme 38.7765
64.74
10 years 23.11
Extreme 23.113
65.86
Manager TitleAgeSince
Chief Executive Officer 61 2019-10-06
Director of Finance/CFO 58 2003-12-31
Chief Operating Officer - 2022-03-31
Director TitleAgeSince
Director/Board Member 71 2003-12-31
Director/Board Member 77 2011-05-31
Director/Board Member 60 2021-01-07
Change 5d. change 1-year change 3-years change Capi.($)
-0.29%-0.34%-7.47%-20.71% 8.46B
-1.13%+1.31%-4.17%-12.35% 45.62B
-1.20%-0.36%+34.42%+21.49% 34.34B
-0.89%+2.25%+28.92%+21.96% 29.46B
-0.97%-3.42%+14.97%-15.48% 28.09B
+0.22%-2.71%+169.96%+369.02% 19.11B
-1.01%+4.38%+58.47%+191.93% 14.78B
+2.31%-6.43%+2,918.75%+3,811.51% 14.25B
-1.59%-0.97%+65.77%+160.33% 14.09B
-1.25%-2.58%+27.38%+1.44% 13.25B
Average -0.58%-1.14%+330.70%+452.91% 22.15B
Weighted average by Cap. -0.74%-0.79%+222.16%+301.18%

Financials

2026 *2027 *
Net sales 2.22B 1.89B 1.75B 1.64B 3.06B 206B 3.13B 20.49B 8.02B 98.94B 8.31B 8.14B 353B 2.35B 2B 1.85B 1.74B 3.25B 218B 3.31B 21.72B 8.5B 105B 8.81B 8.62B 374B
Net income 442M 377M 348M 328M 611M 41.11B 624M 4.09B 1.6B 19.74B 1.66B 1.62B 70.34B 499M 425M 393M 370M 689M 46.37B 704M 4.61B 1.8B 22.27B 1.87B 1.83B 79.34B
Net Debt 589M 501M 464M 437M 814M 54.75B 831M 5.44B 2.13B 26.29B 2.21B 2.16B 93.67B 140M 120M 111M 104M 194M 13.06B 198M 1.3B 508M 6.27B 527M 516M 22.35B
Logo Qiagen N.V.
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Employees
5,654
Date Price Change Volume
26-04-10 40.89 $ -0.29% 1,159,736
26-04-09 41.01 $ -0.63% 1,113,980
26-04-08 41.27 $ +2.84% 1,414,408
26-04-07 40.13 $ -1.59% 1,557,577
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
40.89USD
Average target price
55.46USD
Spread / Average Target
+35.64%

Quarterly revenue - Rate of surprise